Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 54,345 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 54,345 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the sale, the insider directly owned 132,873 shares of the company’s stock, valued at $1,696,788.21. The trade was a 29.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Adam Crystal also recently made the following trade(s):

• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total transaction of $226,221.52.

Tango Therapeutics Price Performance

NASDAQ TNGX traded down $0.26 on Friday, hitting $11.14. The stock had a trading volume of 1,845,900 shares, compared to its average volume of 3,064,300. The business’s fifty day moving average price is $11.35 and its 200 day moving average price is $9.20. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -11.98 and a beta of 1.75. Tango Therapeutics, Inc. has a 52-week low of $1.03 and a 52-week high of $13.60.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vivo Capital LLC acquired a new stake in Tango Therapeutics during the second quarter valued at $3,072,000. Geode Capital Management LLC raised its position in shares of Tango Therapeutics by 27.9% in the second quarter. Geode Capital Management LLC now owns 1,768,913 shares of the company’s stock worth $9,058,000 after acquiring an additional 385,476 shares during the period. Great Lakes Advisors LLC purchased a new stake in shares of Tango Therapeutics during the 3rd quarter worth about $3,560,000. Candriam S.C.A. acquired a new stake in shares of Tango Therapeutics during the 2nd quarter valued at about $3,629,000. Finally, Stempoint Capital LP acquired a new stake in shares of Tango Therapeutics during the 2nd quarter valued at about $1,069,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on TNGX. Weiss Ratings restated a “sell (e+)” rating on shares of Tango Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus initiated coverage on Tango Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 target price on the stock. Wall Street Zen upgraded Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Mizuho began coverage on Tango Therapeutics in a research report on Monday. They set an “outperform” rating and a $19.00 price target for the company. Finally, Guggenheim increased their price objective on Tango Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.